Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives $74.50 Consensus Target Price from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $74.50.

A number of brokerages have commented on LNTH. JMP Securities decreased their price objective on Lantheus from $112.00 to $73.00 and set a “market outperform” rating for the company in a research report on Thursday, August 7th. Mizuho decreased their price target on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, August 7th. Truist Financial set a $63.00 price objective on shares of Lantheus and gave the company a “hold” rating in a research note on Monday, August 11th. Weiss Ratings reissued a “hold (c-)” rating on shares of Lantheus in a research note on Wednesday, October 8th. Finally, The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th.

Insider Activity

In related news, insider Rajiv A. Patel sold 3,365,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,812,000 shares of company stock worth $382,427,380. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of LNTH. Elevation Point Wealth Partners LLC acquired a new position in Lantheus during the second quarter worth $26,000. Osterweis Capital Management Inc. bought a new stake in shares of Lantheus during the 2nd quarter worth about $36,000. Signaturefd LLC increased its holdings in shares of Lantheus by 36.5% during the 1st quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 116 shares during the last quarter. Quarry LP raised its stake in shares of Lantheus by 2,350.0% in the 1st quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 470 shares in the last quarter. Finally, Tripletail Wealth Management LLC acquired a new stake in Lantheus in the 3rd quarter worth approximately $68,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 1.8%

Shares of NASDAQ:LNTH opened at $56.60 on Thursday. The firm has a 50 day simple moving average of $53.92 and a 200 day simple moving average of $72.72. Lantheus has a 52 week low of $47.25 and a 52 week high of $118.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The company has a market cap of $3.85 billion, a PE ratio of 15.05 and a beta of 0.09.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a net margin of 17.82% and a return on equity of 34.06%. As a group, research analysts expect that Lantheus will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.